221 related articles for article (PubMed ID: 19648604)
1. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
Robert C; Ghiringhelli F
Oncologist; 2009 Aug; 14(8):848-61. PubMed ID: 19648604
[TBL] [Abstract][Full Text] [Related]
2. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
Weber J
Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
[TBL] [Abstract][Full Text] [Related]
3. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
4. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
Fong L; Small EJ
J Clin Oncol; 2008 Nov; 26(32):5275-83. PubMed ID: 18838703
[TBL] [Abstract][Full Text] [Related]
5. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
6. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
Ribas A
Oncologist; 2008; 13 Suppl 4():10-5. PubMed ID: 19001146
[TBL] [Abstract][Full Text] [Related]
7. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Buchbinder EI; McDermott DF
Clin Ther; 2015 Apr; 37(4):755-63. PubMed ID: 25746738
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of the anti-CTLA-4 antibody tremelimumab.
Ribas A
Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
[TBL] [Abstract][Full Text] [Related]
12. Recent advances using anti-CTLA-4 for the treatment of melanoma.
Sarnaik AA; Weber JS
Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
[TBL] [Abstract][Full Text] [Related]
13. The role of the CTLA4 blockade in the treatment of malignant melanoma.
Cranmer LD; Hersh E
Cancer Invest; 2007 Oct; 25(7):613-31. PubMed ID: 18027152
[TBL] [Abstract][Full Text] [Related]
14. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Yuan J; Gnjatic S; Li H; Powel S; Gallardo HF; Ritter E; Ku GY; Jungbluth AA; Segal NH; Rasalan TS; Manukian G; Xu Y; Roman RA; Terzulli SL; Heywood M; Pogoriler E; Ritter G; Old LJ; Allison JP; Wolchok JD
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20410-5. PubMed ID: 19074257
[TBL] [Abstract][Full Text] [Related]
16. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
17. [Antibody therapies for melanoma].
Kiniwa Y; Okuyama R
Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
Simeone E; Ascierto PA
J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
[TBL] [Abstract][Full Text] [Related]
19. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
Agarwala SS
Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
[TBL] [Abstract][Full Text] [Related]
20. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.
Calabrò L; Danielli R; Sigalotti L; Maio M
Semin Oncol; 2010 Oct; 37(5):460-7. PubMed ID: 21074061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]